Insider Trading - Nussbaum Ran
Real time insider trading transaction history:
- Insiders must file a Form 4 covering their trades within two business days.
- Section 16 prohibits insiders from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2017-05-09 Purchase | 2017-05-11 2:02 pm | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 9,832 | $69.11 | $679,474 | 2,632 (Indirect Direct) | View |
| 2018-03-21 Purchase | 2018-03-23 4:20 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 12,600 | $7.7643 | $97,830 | 427,063 (Indirect) | View |
| 2018-04-30 Purchase | 2018-05-01 4:34 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 350,000 | $9.75 | $3,412,500 | 520,396 (Indirect) | View |
| 2018-05-18 Purchase | 2018-05-18 5:41 pm | ARQULE INC | ARQL | Nussbaum Ran Director | 8,611 | $3.29 | $28,330 | 8,611 (Direct) | View |
| 2018-05-18 Purchase(A) | 2018-05-22 09:22 am | ARQULE INC | ARQL | Nussbaum Ran Director | 8,611 | $3.29 | $28,330 | 8,611 (Indirect) | View |
| 2018-07-13 Purchase | 2018-10-22 2:54 pm | ARQULE INC | ARQL | Nussbaum Ran Director | 181,818 | $5.5 | $999,999 | 1,630,657 (Indirect) | View |
| 2019-06-24 Purchase | 2019-06-26 4:51 pm | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 200,000 | $9 | $1,800,000 | 24,000 (Indirect) | View |
| 2019-06-27 Purchase | 2019-07-01 11:50 am | ARQULE INC | ARQL | Nussbaum Ran Director | 307,692 | $9.75 | $2,999,997 | 36,923 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:16 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-11-17 Purchase | 2020-11-19 4:40 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2021-05-13 Purchase | 2021-05-17 07:02 am | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 5,925,925 | $1.35 | $7,999,999 | 616,592 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2017-06-20 Option Award | 2017-06-22 2:37 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 2,410 | $0 | 4,360 (Direct) | View |
| 2017-06-20 Option Award | 2017-06-22 2:37 pm | N/A 2027-06-19 | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 8,810 | $0 | 8,810 (Direct) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 4,360 | $0 | 0 (Direct) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 3,520 | $0 | 0 (Indirect) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 2,651 | $0 | 0 (Indirect) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 1,029 | $0 | 0 (Indirect) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A N/A | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 2,632 | $0 | 0 (Indirect) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A 2024-03-24 | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 50,000 | $178.65 | 0 (Direct) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A 2025-06-08 | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 10,000 | $120.77 | 0 (Direct) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A 2026-05-31 | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 7,000 | $129.13 | 0 (Direct) | View |
| 2017-10-03 Disposition | 2017-10-05 8:26 pm | N/A 2027-06-19 | Kite Pharma Inc. | KITE | Nussbaum Ran Director | 8,810 | $88.79 | 0 (Direct) | View |
| 2017-11-08 Option Award | 2017-11-09 12:14 pm | N/A 2027-11-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 30,000 | $0 | 30,000 (Direct) | View |
| 2018-05-08 Option Award | 2018-05-10 12:45 pm | N/A 2028-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 1,762,000 | $0 | 1,762,000 (Indirect) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 3,259,000 | $0 | 3,259,000 (Indirect) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 1,587,000 | $0 | 1,587,000 (Indirect) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 476,000 | $0 | 476,000 (Indirect) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 880,000 | $0 | 880,000 (Indirect) | View |
| 2018-05-08 Other | 2018-05-25 4:30 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 428,000 | $0 | 428,000 (Indirect) | View |
| 2018-06-15 Option Award | 2018-06-19 6:17 pm | N/A 2028-06-15 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2019-05-14 Option Award | 2019-05-15 12:44 pm | N/A 2029-05-13 | ARQULE INC | ARQL | Nussbaum Ran Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2019-05-29 Option Award | 2019-05-29 5:21 pm | N/A 2029-05-29 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2019-05-29 Option Award | 2019-05-30 3:45 pm | N/A 2029-05-29 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2019-06-03 Option Award | 2019-06-05 4:55 pm | N/A 2029-06-02 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 30,476 | $1.75 | 1,913,166 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 56,368 | $1.75 | 3,538,592 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 27,442 | $1.75 | 1,723,115 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A 2021-10-20 | ARQULE INC | ARQL | Nussbaum Ran Director | 30,476 | $0 | 445,524 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A 2021-10-20 | ARQULE INC | ARQL | Nussbaum Ran Director | 56,368 | $0 | 823,632 (Indirect) | View |
| 2019-09-12 Exercise | 2019-09-16 4:42 pm | N/A 2021-10-20 | ARQULE INC | ARQL | Nussbaum Ran Director | 27,442 | $0 | 400,558 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 445,524 | $1.75 | 2,358,690 (Indirect) | View |
| 2019-12-24 Tax Withholding | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 38,770 | $20.11 | 2,319,920 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 823,632 | $1.75 | 4,362,224 (Indirect) | View |
| 2019-12-24 Tax Withholding | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 71,674 | $20.11 | 4,290,550 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 400,558 | $1.75 | 2,123,673 (Indirect) | View |
| 2019-12-24 Tax Withholding | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 34,857 | $20.11 | 2,088,816 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 445,524 | $0 | 0 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 823,632 | $0 | 0 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 400,558 | $0 | 0 (Indirect) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 2,319,920 | $20 | 0 (Indirect) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 4,290,550 | $20 | 0 (Indirect) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 2,088,816 | $20 | 0 (Indirect) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 36,923 | $20 | 0 (Indirect) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 8,611 | $20 | 0 (Indirect) | View |
| 2020-01-16 Disposition | 2020-01-16 3:57 pm | N/A 2027-11-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 30,000 | $0 | 0 (Direct) | View |
| 2020-01-16 Disposition | 2020-01-16 3:57 pm | N/A 2028-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 20,000 | $0 | 0 (Direct) | View |
| 2020-01-16 Disposition | 2020-01-16 3:57 pm | N/A 2029-05-13 | ARQULE INC | ARQL | Nussbaum Ran Director | 40,000 | $0 | 0 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 1,734,395 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 844,371 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 937,735 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 1,903,702 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 926,796 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 1,029,273 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 68,654 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 2,067,314 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 1,015,256 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 1,108,926 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 105,512 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 0 (Indirect) | View |
| 2020-05-20 Option Award | 2020-05-22 4:10 pm | N/A 2030-05-20 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2020-06-08 Option Award | 2020-06-10 6:41 pm | N/A 2030-06-07 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2020-06-17 Option Award | 2020-06-19 6:38 pm | N/A 2030-06-17 | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 17,000 (Direct) | View |
| 2021-01-22 Equity Swap | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 1,576,881 | $0 | 0 (Indirect) | View |
| 2021-01-22 Disposition | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 0 (Direct) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,465,199 (Indirect) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 0 (Indirect) | View |
| 2021-05-19 Option Award | 2021-05-20 4:10 pm | N/A 2031-05-19 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2021-06-01 Option Award | 2021-06-03 5:34 pm | N/A 2031-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $5 | 1,433,928 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $0 | 0 (Indirect) | View |
| 2021-03-25 Option Award | 2021-06-09 1:42 pm | N/A 2031-06-06 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 6,817 | $0 | 6,817 (Indirect) | View |
| 2021-03-25 Option Award | 2021-06-09 1:42 pm | N/A 2031-06-06 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 3,183 | $0 | 3,183 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:46 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,431,717 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:46 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 0 (Indirect) | View |